Research Finder JSON Trials - Stand Up To Cancer

Research Finder JSON Trials

{“posts”:[{“title”:”EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/180350″,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”start_date”:”October 2019″,”status”:”Open”,”trial_id”:”NCT03618381″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03618381?term=NCT03618381&rank=1″,”cancer_type_terms_string”:”Brain/Nervous System, Liver, Pediatric – Solid Tumor, Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Stand Up To Cancer (SU2C)/Melanoma Research Alliance (MRA) Genomics Enabled Medicine for Melanoma (G.E.M.M.) Trial”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/84236″,”research_project”:”SU2C–Melanoma Research Alliance Melanoma Dream Team: Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/melanoma-braf-wildtype-dream-team/”,”start_date”:”May 2019″,”status”:”Open”,”trial_id”:”NCT02094872″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02094872?term=NCT02094872&rank=1″,”cancer_type_terms_string”:”Melanoma”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”GENetic Education Risk Assessment and TEsting Study (GENERATE)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT03762590?term=NCT03762590&rank=1″,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team: Intercepting Pancreatic Cancer in High-Risk Cohorts”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/pancreatic-interception-high-risk-cohorts-dream-team/”,”start_date”:”April 2019″,”status”:”Open”,”trial_id”:”NCT03762590″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03762590?term=NCT03762590&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”},{“title”:”EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/182092″,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”start_date”:”March 2019″,”status”:”Open”,”trial_id”:”NCT03638167″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03638167?term=NCT03638167&rank=1″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/182278″,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”start_date”:”January 2019″,”status”:”Open”,”trial_id”:”NCT03649321″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03649321?term=NCT03649321&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/174996″,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”start_date”:”December 2018″,”status”:”Open”,”trial_id”:”NCT03520790″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03520790?term=NCT03520790&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”CFI-400945 in Patients With Advanced/Metastatic Breast Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/181202″,”research_project”:”SU2C Canada–Canadian Cancer Society Breast Cancer Dream Team: Translational Development of Novel Drugs Targeting Tumor Vulnerabilities”,”research_project_url”:”http://www.standuptocancer.ca/en/dream_teams/view/cbcf_breast_cancer_dream_team”,”start_date”:”December 2018″,”status”:”Open”,”trial_id”:”NCT03624543″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03624543?term=NCT03624543&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/183540″,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”start_date”:”November 2018″,”status”:”Open”,”trial_id”:”NCT03684889″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03684889?term=NCT03684889&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Pediatric – Blood Related”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT03689595?term=NCT03689595&rank=1″,”research_project”:”SU2C Multiple Myeloma Dream Team: Screening and Interception of Precursor Myeloma”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/precursor-myeloma-dream-team/”,”start_date”:”October 2018″,”status”:”Open”,”trial_id”:”NCT03689595″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03689595?term=NCT03689595&rank=1″,”cancer_type_terms_string”:”Multiple Myeloma”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”},{“title”:”Dabrafenib + Trametinib + PDR001 In Colorectal Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/183333″,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”start_date”:”October 2018″,”status”:”Open”,”trial_id”:”NCT03668431″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03668431?term=NCT03668431&rank=1″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/177095″,”research_project”:”SU2C–Lustgarten Foundation For Pancreatic Research Interception Research Team: Developing Novel Approaches to Treat and Evaluate Early Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/research-teams/pancreatic-cancer-interception-research-team/”,”start_date”:”August 2018″,”status”:”Open”,”trial_id”:”NCT03563248″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03563248?term=NCT03563248&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Immunotherapy, Other”,”grant_type_terms_string”:”Research Team”},{“title”:”HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/173443″,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”start_date”:”July 2018″,”status”:”Open”,”trial_id”:”NCT03500991″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03500991?term=NCT03500991&rank=1″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma (NeoACTIVATE)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/176599″,”research_project”:”SU2C Catalyst® Research Grant with Support from Genentech: Neoadjuvant Therapy for Patients with High-Risk Stage III Melanoma”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”June 2018″,”status”:”Open”,”trial_id”:”NCT03554083″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03554083?term=NCT03554083&rank=1″,”cancer_type_terms_string”:””,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Catalyst Team”},{“title”:”MK-3475 + Trametinib in Advanced KRAS Mutant Non-Small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/146657″,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”start_date”:”June 2018″,”status”:”Open”,”trial_id”:”NCT03299088″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03299088?term=NCT03299088&rank=1″,”cancer_type_terms_string”:””,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/177835″,”research_project”:”SU2C Catalyst® Research Grant with Support from Genentech: Immunotherapy Combination Strategies in ER-positive Metastatic Breast Cancer”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”June 2018″,”status”:”Open”,”trial_id”:”NCT03566485″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03566485?term=NCT03566485&rank=1″,”cancer_type_terms_string”:””,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Catalyst Team”},{“title”:”A Phase II Trial of Immunotherapy with MEDI4736 with Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant NSCLC”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT03004105?term=NCT03004105&rank=1″,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”start_date”:”May 2018″,”status”:”Closed”,”trial_id”:”NCT03004105″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03004105?term=NCT03004105&rank=1″,”cancer_type_terms_string”:””,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma (Inbraced)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/118386″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”May 2018″,”status”:”Open”,”trial_id”:”NCT02914405″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02914405?term=NCT02914405&rank=1″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/170495″,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”start_date”:”March 2018″,”status”:”Open”,”trial_id”:”NCT03448393″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03448393?term=NCT03448393&rank=1″,”cancer_type_terms_string”:”Pediatric – Blood Related”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Treatment of Relapsed or Refractory Neuroblastoma With Expanded Haploidentical NK Cells and Hu14.18-IL2″,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/139008″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”March 2018″,”status”:”Open”,”trial_id”:”NCT03209869″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03209869?term=NCT03209869&rank=1″,”cancer_type_terms_string”:”Brain/Nervous System, Head and Neck, Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”BATTLE-Immunotherapy: a Randomized Phase II trial of trametinib in combination with MK-3475 anti-PD1 antibody versus MK-3475 anti-PD1 antibody in advanced, refractory to frontline chemotherapy NSCLC”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/137176″,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”start_date”:”February 2018″,”status”:”Open”,”trial_id”:”NCT03225664″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03225664?term=NCT03225664&rank=1″,”cancer_type_terms_string”:””,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/139192″,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”start_date”:”February 2018″,”status”:”Open”,”trial_id”:”NCT03257761″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03257761?term=NCT03257761&rank=1″,”cancer_type_terms_string”:”Bile Duct, Gall Bladder, Liver, Pancreatic”,”treatment_type_terms_string”:”Epigenetic Therapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A First in Human Phase I trial of a Vaccine Targeting Mutant KRAS and Mesothelin Epitopes in Combination with an anti-PD-1 Antibody in Patients with Previously Treated, Metastatic, KRAS mutant NSCLC”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT03371381?term=NCT03371381&rank=1″,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”start_date”:”January 2018″,”status”:”Closed”,”trial_id”:”NCT03371381″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03371381?term=NCT03371381&rank=1″,”cancer_type_terms_string”:””,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/166803″,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”start_date”:”January 2018″,”status”:”Open”,”trial_id”:”NCT03415854″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03415854?term=NCT03415854&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/117857″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”January 2018″,”status”:”Open”,”trial_id”:”NCT02881242″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02881242?term=NCT02881242&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A SU2C Catalyst® Randomized Phase II Trail of The PD1 Inhibitor Pembrolizumab (Keytruda®) With or Without a Vitamin D Receptor Agonist Paricalcitol (Zemplar®) in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (With No Further Improvement in Their Tumor)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/150695″,”research_project”:”SU2C Catalyst® Research Grant with Support from Merck: Targeting VDR to make Pancreatic Cancer Competent for Immunotherapy”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”December 2017″,”status”:”Open”,”trial_id”:”NCT03331562″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03331562?term=NCT03331562&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Catalyst Team”},{“title”:”A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/152417″,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”start_date”:”December 2017″,”status”:”Open”,”trial_id”:”NCT03336216″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03336216?term=NCT03336216&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (AA NABPLAGEM)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/166598″,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”start_date”:”December 2017″,”status”:”Open”,”trial_id”:”NCT03410030″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03410030?term=NCT03410030&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer (GELATO)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/134653″,”research_project”:”SU2C−Dutch Cancer Society Translational Research Team: Prospective Use of DNA-Guided Personalized Cancer Treatment”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/research-teams/dna-guided-care-research-team/”,”start_date”:”November 2017″,”status”:”Open”,”trial_id”:”NCT03147040″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03147040?term=NCT03147040&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Research Team”},{“title”:”Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/135789″,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”start_date”:”November 2017″,”status”:”Open”,”trial_id”:”NCT03179943″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03179943?term=NCT03179943&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Epigenetic Therapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/169905″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”November 2017″,”status”:”Open”,”trial_id”:”NCT03330691″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03330691?term=NCT03330691&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Lymphoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/135789″,”research_project”:”SU2C Catalyst® Research Grant with Support from Genentech: Overcoming Urothelial Cancer Atezolizumab Resistance by Epigenetic Therapy”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”November 2017″,”status”:”Open”,”trial_id”:”NCT03179943″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03179943?term=NCT03179943&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Epigenetic Therapy, Immunotherapy”,”grant_type_terms_string”:”Catalyst Team”},{“title”:”A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Non-Small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/137195″,”research_project”:”SU2C Catalyst® Research Grant with Support from BMS: Tumor Infiltrating Lymphocyte Adoptive T Cell Therapy for Non-Small Cell Lung Cancer (NSCLC)”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”October 2017″,”status”:”Open”,”trial_id”:”NCT03215810″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03215810?term=NCT03215810&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Catalyst Team”},{“title”:”CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19Positive B Acute Lymphoblastic Leukemia:”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/139806″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”October 2017″,”status”:”Open”,”trial_id”:”NCT03241940″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03241940?term=NCT03241940&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Lymphoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase 2 Study of EGF816 and gefitinib in TKI-mutant Non-Small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/144520″,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”start_date”:”October 2017″,”status”:”Open”,”trial_id”:”NCT03292133″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03292133?term=NCT03292133&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”},{“title”:”A Phase II Study of EGF816 and Gefitinib in TK1-Naïve EGFR-Mutant Non-small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/144520″,”research_project”:”SU2C–National Science Foundation Lung Cancer Convergence Research Team: Genetic, Epigenetic, and Immunological Underpinnings of Cancer Evolution Through Treatment”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/cancer-evolution-convergence-team/”,”start_date”:”October 2017″,”status”:”Open”,”trial_id”:”NCT03292133″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03292133?term=NCT03292133&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Convergence Team”},{“title”:”CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/177928″,”research_project”:”SU2C Canada–Canadian Cancer Society Breast Cancer Dream Team: Translational Development of Novel Drugs Targeting Tumor Vulnerabilities”,”research_project_url”:”http://www.standuptocancer.ca/en/dream_teams/view/cbcf_breast_cancer_dream_team”,”start_date”:”October 2017″,”status”:”Open”,”trial_id”:”NCT03568422″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03568422?term=NCT03568422&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I Study of Human Chimeric Antigen Receptor Modified T Cells (CAR T Cells) in Patients With Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/149175″,”research_project”:”SU2C–Lustgarten Foundation CAR T Research Team: Chimeric Antigen Receptor T Cell (CAR T) Therapy for Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/research-teams/car-t-therapy-for-pancreatic-cancer-research-team/”,”start_date”:”September 2017″,”status”:”Open”,”trial_id”:”NCT03323944″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03323944?term=NCT03323944&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Research Team”},{“title”:”A Phase 1b pharmacodynamic study of neoadjuvant paricalcitol in resectable pancreatic cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/145961″,”research_project”:”SU2C–National Science Foundation–Lustgarten Foundation Pancreatic Cancer Convergence Research Team: Liberating T-Cell Mediated Immunity to Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/mediated-immunity-in-pancreatic-cancer-convergence-team/”,”start_date”:”September 2017″,”status”:”Open”,”trial_id”:”NCT03300921″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03300921?term=NCT03300921&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”},{“title”:”Open Label, Phase II Study of TGR-1202 in Patients With Relapsed or Refractory (R/R) Grade 1, 2, or 3A Follicular Lymphoma (FL)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/134980″,”research_project”:”Laura Ziskin Prize: Phosphatidylinositol 3-kinase d Inhibition to Treat Patients With Relapsed or Refractory Follicular Lymphoma”,”research_project_url”:””,”start_date”:”August 2017″,”status”:”Open”,”trial_id”:”NCT03178201″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03178201?term=NCT03178201&rank=1″,”cancer_type_terms_string”:”Lymphoma”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Laura Ziskin Prize”},{“title”:”A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/135356″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”August 2017″,”status”:”Open”,”trial_id”:”NCT03186118″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03186118?term=NCT03186118&rank=1″,”cancer_type_terms_string”:”Leukemia (all types)”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I/Ib Trial of Combined 5’Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain and Solid Tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/137416″,”research_project”:”SU2C Canada Cancer Stem Cell Dream Team: Targeting Brain Tumour Stem Cell Epigenetic and Molecular Networks”,”research_project_url”:”http://www.standuptocancer.ca/en/dream_teams/view/cancer_stem_cell_dream_team”,”start_date”:”August 2017″,”status”:”Open”,”trial_id”:”NCT03206021″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03206021?term=NCT03206021&rank=1″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I/Ib study of combined pembrolizumab plus guadecitabine and mocetinostat for patients with advanced NSCLC”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/137434″,”research_project”:”SU2C Catalyst® Research Grant with Support from Merck: Combined Epigenetic Therapy and Pembrolizumab for Advanced Non-Small Cell Lung Cancer (NSCLC)”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”August 2017″,”status”:”Open”,”trial_id”:”NCT03220477″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03220477?term=NCT03220477&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Epigenetic Therapy, Immunotherapy”,”grant_type_terms_string”:”Catalyst Team”},{“title”:”Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/137434″,”research_project”:”SU2C Catalyst® Research Grant with Support from Genentech: Overcoming Urothelial Cancer Atezolizumab Resistance by Epigenetic Therapy”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”August 2017″,”status”:”Open”,”trial_id”:”NCT03220477″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03220477?term=NCT03220477&rank=1″,”cancer_type_terms_string”:””,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Catalyst Team”},{“title”:”A Pilot Study of Carboplatin and Paclitaxel Chemotherapy with Nivolumab in Patients with Ovarian Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/138577″,”research_project”:”SU2C Gynecologic Cancers Convergence Research Team: Connecting Immune Health and Tumor Biology in Gynecologic Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/gynecologic-cancers-convergence-research-team/”,”start_date”:”August 2017″,”status”:”Open”,”trial_id”:”NCT03245892″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03245892?term=NCT03245892&rank=1″,”cancer_type_terms_string”:”Ovarian”,”treatment_type_terms_string”:”Chemotherapy, Immunotherapy”,”grant_type_terms_string”:”Convergence Team”},{“title”:”A Phase II Trial of Single-Agent Nivolumab in Patients with Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/139661″,”research_project”:”SU2C Gynecologic Cancers Convergence Research Team: Connecting Immune Health and Tumor Biology in Gynecologic Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/gynecologic-cancers-convergence-research-team/”,”start_date”:”August 2017″,”status”:”Open”,”trial_id”:” NCT03241745″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03241745?term=NCT03241745&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Convergence Team”},{“title”:”To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/139682″,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to Treatable Disease”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/transforming-pancreatic-cancer-dream-team/”,”start_date”:”July 2017″,”status”:”Open”,”trial_id”:”NCT03277209″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03277209?term=NCT03277209&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/123504″,”research_project”:”SU2C Catalyst® Research Grant with Support from BMS: Reversing Primary Anti-PD-1 Resistance with Ipilimumab and Nivolumab”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”July 2017″,”status”:”Open”,”trial_id”:”NCT03033576″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03033576?term=NCT03033576&rank=1″,”cancer_type_terms_string”:”Melanoma”,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Catalyst Team”},{“title”:”A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/132128″,”research_project”:”SU2C Catalyst® Research Grant with Support from Merck: Pembrolizumab and Radiation Therapy to improve Outcome in High-Risk Sarcoma”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”July 2017″,”status”:”Open”,”trial_id”:”NCT03092323″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03092323?term=NCT03092323&rank=1″,”cancer_type_terms_string”:”Sarcoma”,”treatment_type_terms_string”:”Immunotherapy, Radiation Therapy, Other”,”grant_type_terms_string”:”Catalyst Team”},{“title”:”Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/138675″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”July 2017″,”status”:”Open”,”trial_id”:”NCT03244306″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03244306?term=NCT03244306&rank=1″,”cancer_type_terms_string”:”Leukemia (all types)”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Nivo only trial: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers; Combo trial pending”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/120816″,”research_project”:”SU2C Catalyst® Research Grant with Support from BMS: Combined Approaches by Immune Checkpoint Inhibition for Hypermutant Cancers”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”May 2017″,”status”:”Open”,”trial_id”:”NCT02992964″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02992964?term=NCT02992964&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Leukemia (all types), Liver, Lung, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Pediatric – Blood Related, Pediatric – Solid Tumor, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Catalyst Team”},{“title”:”Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/132958″,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”start_date”:”May 2017″,”status”:”Open”,”trial_id”:”NCT03104439″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03104439?term=NCT03104439&rank=1″,”cancer_type_terms_string”:”Colorectal, Pancreatic”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/134115″,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”start_date”:”May 2017″,”status”:”Open”,”trial_id”:”NCT03146962″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03146962?term=NCT03146962&rank=1″,”cancer_type_terms_string”:”Colorectal, Lung, Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”MAGENTA (Making Genetic Testing Available)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/120819″,”research_project”:”SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/dna-repair-thearpies-for-ovarian-cancer-dream-team/”,”start_date”:”April 2017″,”status”:”Open”,”trial_id”:”NCT02993068″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02993068?term=NCT02993068&rank=1″,”cancer_type_terms_string”:”Breast, Ovarian”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”},{“title”:”A phase II, international open label trial of Minnelide™ in patients with refractory pancreatic cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/132229″,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”start_date”:”April 2017″,”status”:”Open”,”trial_id”:”NCT03117920″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03117920?term=NCT03117920&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/123149″,”research_project”:”SU2C–Lustgarten Foundation CAR T Research Team: Chimeric Antigen Receptor T Cell (CAR T) Therapy for Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/research-teams/car-t-therapy-for-pancreatic-cancer-research-team/”,”start_date”:”March 2017″,”status”:”Open”,”trial_id”:”NCT03054298″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03054298?term=NCT03054298&rank=1″,”cancer_type_terms_string”:”Lung, Mesothelioma, Ovarian”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Research Team”},{“title”:”NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy with PD-1 Blockade”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/114985″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”January 2017″,”status”:”Open”,”trial_id”:”NCT02775292″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02775292?term=NCT02775292&rank=1″,”cancer_type_terms_string”:”Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Leukemia (all types), Lung, Lymphoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Pediatric – Blood Related, Pediatric – Solid Tumor, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase Ib/II trial to test the safety and efficacy of vaccination with HPV16 E711-19 nanomer for the treatment of incurable HPV-16 related oropharyngeal, cervical and anal cancer in HLA-A*02 positive patients”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/117526″,”research_project”:”SU2C–Farrah Fawcett Foundation Human Papillomavirus (HPV) Research Team: Therapeutic CD8 Vaccines Against Conserved E7 HPV Epitopes Identified by MS”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/research-teams/hpv-research-team/”,”start_date”:”December 2016″,”status”:”Open”,”trial_id”:”NCT02865135″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02865135?term=NCT02865135&rank=1″,”cancer_type_terms_string”:”Cervical, Colorectal, Head and Neck”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Research Team”},{“title”:”A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7- H3 Expressing Pediatric Cancers”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/120553″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”December 2016″,”status”:”Open”,”trial_id”:”NCT02982941″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02982941?term=NCT02982941&rank=1″,”cancer_type_terms_string”:”Pediatric – Solid Tumor, Sarcoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase 1, Open Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-007 as a Single Agent in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/121196″,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”start_date”:”December 2016″,”status”:”Open”,”trial_id”:”NCT03006172″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT03006172?term=NCT03006172&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”},{“title”:”A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/115572″,”research_project”:”SU2C Canada–Canadian Cancer Society Breast Cancer Dream Team: Translational Development of Novel Drugs Targeting Tumor Vulnerabilities”,”research_project_url”:”http://www.standuptocancer.ca/en/dream_teams/view/cbcf_breast_cancer_dream_team”,”start_date”:”November 2016″,”status”:”Open”,”trial_id”:” NCT02792465″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02792465?term=NCT02792465&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/118929″,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”start_date”:”November 2016″,”status”:”Open”,”trial_id”:”NCT02935361″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02935361?term=NCT02935361&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Multiple Myeloma”,”treatment_type_terms_string”:”Epigenetic Therapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II Study of Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/118326″,”research_project”:”SU2C Endometrial Cancers Convergence Research Team: Responders and Nonresponders to Endometrial Cancers With Mismatch Repair Deficiencies”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/endometrial-cancers-convergence-research-team/”,”start_date”:”September 2016″,”status”:”Open”,”trial_id”:”NCT02899793″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02899793?term=NCT02899793&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Convergence Team”},{“title”:”Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/112710″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”September 2016″,”status”:”Open”,”trial_id”:”NCT02709889″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02709889?term=NCT02709889&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”EVITA (Epigenetics, Vitamin C and Abnormal Hematopoesis) – Restoring physiological vitamin C levels to the normal range: Influence on epigenetic regulation in normal and malignant hematopoiesis”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02877277?term=NCT02877277&rank=1″,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”start_date”:”August 2016″,”status”:”Open”,”trial_id”:”NCT02877277″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02877277?term=NCT02877277&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Multiple Myeloma”,”treatment_type_terms_string”:”Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/117457″,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”start_date”:”August 2016″,”status”:”Open”,”trial_id”:”NCT02861300″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02861300?term=NCT02861300&rank=1″,”cancer_type_terms_string”:”Colorectal, Other”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/124881″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”August 2016″,”status”:”Open”,”trial_id”:”NCT02906371″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02906371?term=NCT02906371&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Lymphoma, Pediatric – Blood Related”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Multicenter Phase 1/2 Study of Combination Therapy w/ DNA Methyltransferase Inhibitor Decitabine & Poly ADP Ribose Polymerase Inhibitor Talazoparib for Untreated AML in Adults Unfit for Cytotoxic Chemotherapy or R/R AML”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/131510″,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”start_date”:”August 2016″,”status”:”Open”,”trial_id”:”NCT02878785″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02878785?term=NCT02878785&rank=1″,”cancer_type_terms_string”:”Leukemia (all types)”,”treatment_type_terms_string”:”Chemotherapy, Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/92555″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”June 2016″,”status”:”Open”,”trial_id”:”NCT02339168″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02339168?term=NCT02339168&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Genetic Predictors of Benefit to Pembrolizumab”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/112713″,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”start_date”:”May 2016″,”status”:”Open”,”trial_id”:”NCT02710396″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02710396?term=NCT02710396&rank=1″,”cancer_type_terms_string”:”Bladder, Brain/Nervous System, Esophogeal, Head and Neck, Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase I/II Study of CX5461″,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/112949″,”research_project”:”SU2C Canada–Canadian Cancer Society Breast Cancer Dream Team: Translational Development of Novel Drugs Targeting Tumor Vulnerabilities”,”research_project_url”:”http://www.standuptocancer.ca/en/dream_teams/view/cbcf_breast_cancer_dream_team”,”start_date”:”May 2016″,”status”:”Open”,”trial_id”:”NCT02719977″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02719977?term=NCT02719977&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”WISP (Women Choosing Surgical Prevention)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/114324″,”research_project”:”SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/dna-repair-thearpies-for-ovarian-cancer-dream-team/”,”start_date”:”May 2016″,”status”:”Open”,”trial_id”:”NCT02760849″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02760849?term=NCT02760849&rank=1″,”cancer_type_terms_string”:”Breast, Ovarian”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02705469?term=NCT02705469&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”May 2016″,”status”:”Open”,”trial_id”:”NCT02705469″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02705469?term=NCT02705469&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A PHASE II PILOT TRIAL OF NIVOLUMAB + ALBUMIN-BOUND PACLITAXEL +PARICALCITOL + CISPLATIN + GEMCITABINE (NAPPCG) IN PATIENTSWITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTALADENOCARCINOMA”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/114071″,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”start_date”:”April 2016″,”status”:”Open”,”trial_id”:”NCT02754726″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02754726?term=NCT02754726&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Study of Niraparib in Combination with Pembrolizumab in Triple Negative Breast Cancer or Ovarian Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/110079″,”research_project”:”SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/dna-repair-thearpies-for-ovarian-cancer-dream-team/”,”start_date”:”March 2016″,”status”:”Open”,”trial_id”:”NCT02657889″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02657889?term=NCT02657889&rank=1″,”cancer_type_terms_string”:”Breast, Ovarian, Other”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I/II trial of Niraprib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/110079″,”research_project”:”SU2C Catalyst® Research Grant with Support from Merck: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”March 2016″,”status”:”Open”,”trial_id”:”NCT02657889″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02657889?term=NCT02657889&rank=1″,”cancer_type_terms_string”:”Breast, Endometiral/Uterin, Ovarian”,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Catalyst Team”},{“title”:”T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma (iCAR)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/98849″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”February 2016″,”status”:”Open”,”trial_id”:”NCT02442297″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02442297?term=NCT02442297&rank=1″,”cancer_type_terms_string”:”Brain/Nervous System, Head and Neck”,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Dream Team”},{“title”:”Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/108778″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”January 2016″,”status”:”Open”,”trial_id”:”NCT02650414″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02650414?term=NCT02650414&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Lymphoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”TCR-Alpha/Beta and CD19+ depleted KIR/KIR ligandmismatched Haploidentical Hematopoietic Stem Cell Transplant and Zolendronate for Pediatric Relapsed/ Refractory Hematologic Malignancies and High Risk Solid Tumor”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/110835″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”January 2016″,”status”:”Open”,”trial_id”:”NCT02508038″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02508038?term=NCT02508038&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Pediatric – Blood Related, Pediatric – Solid Tumor, Sarcoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase I, Open-Label, Multicentre study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of Ascending Doses of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with MEDI4736 in Patients with Advanced Solid Tumours”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/105142″,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”start_date”:”December 2015″,”status”:”Open”,”trial_id”:”NCT02586987″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02586987?term=NCT02586987&rank=1″,”cancer_type_terms_string”:”Bile Duct, Brain/Nervous System, Breast, Colorectal, Esophogeal, Head and Neck, Lung, Melanoma, Pancreatic”,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Dream Team”},{“title”:”Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/104082″,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”start_date”:”November 2015″,”status”:”Open”,”trial_id”:”NCT02563002″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02563002?term=NCT02563002&rank=1″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/108009″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”November 2015″,”status”:”Open”,”trial_id”:”NCT02624258″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02624258?term=NCT02624258&rank=1″,”cancer_type_terms_string”:”Lymphoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/102454″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”October 2015″,”status”:”Open”,”trial_id”:”NCT02522715″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02522715?term=NCT02522715&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I study of neo-adjuvant RO7009789 alone or neo-adjuvant RO7009789 plus nab-paclitaxel and gemcitabine followed by adjuvant RO7009789 plus nab-paclitaxel and gemcitabine for patients with newly diagnosed resectable pancreatic carcinoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/105145″,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to Treatable Disease”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/transforming-pancreatic-cancer-dream-team/”,”start_date”:”October 2015″,”status”:”Open”,”trial_id”:”NCT02588443″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02588443?term=NCT02588443&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/105206″,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to Treatable Disease”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/transforming-pancreatic-cancer-dream-team/”,”start_date”:”October 2015″,”status”:”Open”,”trial_id”:”NCT02562898″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02562898?term=NCT02562898&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/101503″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”September 2015″,”status”:”Open”,”trial_id”:”NCT02494921″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02494921?term=NCT02494921&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/98353″,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”start_date”:”July 2015″,”status”:”Open”,”trial_id”:”NCT02437136″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02437136?term=NCT02437136&rank=1″,”cancer_type_terms_string”:”Colorectal, Lung, Melanoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers (CAM-PLEX)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02179970?term=NCT02179970&rank=1″,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to Treatable Disease”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/transforming-pancreatic-cancer-dream-team/”,”start_date”:”June 2015″,”status”:”Open”,”trial_id”:”NCT02179970″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02179970?term=NCT02179970&rank=1″,”cancer_type_terms_string”:”Colorectal, Ovarian, Pancreatic”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide (PRIMCAB)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02379390?term=NCT02379390&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”June 2015″,”status”:”Open”,”trial_id”:”NCT02379390″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02379390?term=NCT02379390&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/96077″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”May 2015″,”status”:”Open”,”trial_id”:”NCT02408016″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02408016?term=NCT02408016&rank=1″,”cancer_type_terms_string”:”Lung, Mesothelioma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase I Clinical Trial of Malignant Pleural Disease Treated with Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/96524″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”May 2015″,”status”:”Open”,”trial_id”:”NCT02414269″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02414269?term=NCT02414269&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Leukemia (all types), Liver, Lung, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA): A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/98216″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”April 2015″,”status”:”Open”,”trial_id”:”NCT02435849″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02435849?term=NCT02435849&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Pediatric – Blood Related”,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer who Have Progressed or Recurred Following Treatment with a Platinum Agent”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/94279″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”March 2015″,”status”:”Open”,”trial_id”:”NCT02387996″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02387996?term=NCT02387996&rank=1″,”cancer_type_terms_string”:”Bladder, Colorectal, Endometiral/Uterin”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T-Cells and Anti-CTLA4 for Patients With Metastatic Melanoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/81674″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”January 2015″,”status”:”Open”,”trial_id”:”NCT02027935″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02027935?term=NCT02027935&rank=1″,”cancer_type_terms_string”:”Melanoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/88733″,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to Treatable Disease”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/transforming-pancreatic-cancer-dream-team/”,”start_date”:”December 2014″,”status”:”Open”,”trial_id”:”NCT02243371″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02243371?term=NCT02243371&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/112955″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”December 2014″,”status”:”Open”,”trial_id”:”NCT02315612″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02315612?term=NCT02315612&rank=1″,”cancer_type_terms_string”:”Lymphoma, Pediatric – Blood Related”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/102440″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”December 2014″,”status”:”Open”,”trial_id”:”NCT02525068″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02525068?term=NCT02525068&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/90571″,”research_project”:”SU2C Catalyst® Research Grant with Support from BMS: Immunotherapy to Prevent Progression in Multiple Myeloma”,”research_project_url”:”https://progress.standuptocancer.org/catalyst”,”start_date”:”December 2014″,”status”:”Open”,”trial_id”:”NCT02279394″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02279394?term=NCT02279394&rank=1″,”cancer_type_terms_string”:”Multiple Myeloma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Catalyst Team”},{“title”:”Phase I randomized pre-surgical study evaluating anti- PD1 antibody vs. anti-PD1 antibody + bevacizumab vs. anti-CTLA-4 + bevacizumab in patients with metastatic renal cell carcinoma who are eligible for cytoreductive nephrectomy”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/87614″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”November 2014″,”status”:”Open”,”trial_id”:”NCT02210117″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02210117?term=NCT02210117&rank=1″,”cancer_type_terms_string”:”Kidney”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/90898″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”November 2014″,”status”:”Open”,”trial_id”:”NCT02312557″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02312557?term=NCT02312557&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01″,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/124656″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”November 2014″,”status”:”Open”,”trial_id”:”NCT02311621″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02311621?term=NCT02311621&rank=1″,”cancer_type_terms_string”:”Brain/Nervous System, Head and Neck, Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase 11 Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women with ER-Positive/HER2-Negative, Early Stage Breast Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02273973?term=NCT02273973&rank=1″,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”start_date”:”November 2014″,”status”:”Open”,”trial_id”:”NCT02273973″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02273973?term=NCT02273973&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”},{“title”:”Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/89288″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”October 2014″,”status”:”Open”,”trial_id”:”NCT02254785″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02254785?term=NCT02254785&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Safety and Immune Correlates of Preoperative Anti-Programmed Death-1 Antibody, Nivolumab, in Non-Small-Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/89154″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”September 2014″,”status”:”Open”,”trial_id”:”NCT02259621″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02259621?term=NCT02259621&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Sequencing Abiraterone and Enzalutamide in mCRPC”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/84943″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”September 2014″,”status”:”Open”,”trial_id”:”NCT02125357″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02125357?term=NCT02125357&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NA_00092076)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/89154″,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”start_date”:”September 2014″,”status”:”Open”,”trial_id”:”NCT02259621″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02259621?term=NCT02259621&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02215161?term=NCT02215161&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”September 2014″,”status”:”Closed”,”trial_id”:”NCT02215161″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02215161?term=NCT02215161&rank=1″,”cancer_type_terms_string”:”Prostate, Other”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02216409?term=NCT02216409&rank=1″,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to Treatable Disease”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/transforming-pancreatic-cancer-dream-team/”,”start_date”:”August 2014″,”status”:”Open”,”trial_id”:”NCT02216409″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02216409?term=NCT02216409&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Dream Team”},{“title”:”An observational study to determine T-cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/84667″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”August 2014″,”status”:”Open”,”trial_id”:”NCT02113657″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02113657?term=NCT02113657&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer before or after progression on docetaxel”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/87621″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”August 2014″,”status”:”Open”,”trial_id”:”NCT02207504″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02207504?term=NCT02207504&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/88358″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”August 2014″,”status”:”Open”,”trial_id”:”NCT02228096″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02228096?term=NCT02228096&rank=1″,”cancer_type_terms_string”:”Leukemia (all types)”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”NY-ESO-1TCR Engineered Adoptive Cell Transfer Therapy with CTLA4 Blockade”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02070406?term=NCT02070406&rank=1″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”July 2014″,”status”:”Closed”,”trial_id”:”NCT02070406″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02070406?term=NCT02070406&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase 1b study of ARN-509 combined with everolimus in abiraterone-resistant CPRC at baseline and progression”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/84452″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”April 2014″,”status”:”Open”,”trial_id”:”NCT02106507″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02106507?term=NCT02106507&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/84466″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”April 2014″,”status”:”Open”,”trial_id”:”NCT02111577″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02111577?term=NCT02111577&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/113735″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”March 2014″,”status”:”Open”,”trial_id”:”NCT02374333″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02374333?term=NCT02374333&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Lymphoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of CFI-400945 Fumarate in Patients with Advanced Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/79310″,”research_project”:”SU2C Canada–Canadian Cancer Society Breast Cancer Dream Team: Translational Development of Novel Drugs Targeting Tumor Vulnerabilities”,”research_project_url”:”http://www.standuptocancer.ca/en/dream_teams/view/cbcf_breast_cancer_dream_team”,”start_date”:”March 2014″,”status”:”Open”,”trial_id”:”NCT01954316″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01954316?term=NCT01954316&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”An open label, two-part, phase Ib/II study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the MEK inhibitor trametinib and the BCL-2-family inhibitor navitoclax (ABT-263) in combination in subjects with KRAS mutation-positive advanced solid tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/83686″,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”start_date”:”March 2014″,”status”:”Open”,”trial_id”:”NCT02079740″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02079740?term=NCT02079740&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II neo-adjuvant trial with BKM120, BYL719 or placebo in combination with Letrozole”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01923168?term=NCT01923168&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”March 2014″,”status”:”Open”,”trial_id”:”NCT01923168″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01923168?term=NCT01923168&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02023697?term=NCT02023697&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”March 2014″,”status”:”Open”,”trial_id”:”NCT02023697″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02023697?term=NCT02023697&rank=1″,”cancer_type_terms_string”:”Prostate, Other”,”treatment_type_terms_string”:”Chemotherapy, Radiation Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/81617″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”February 2014″,”status”:”Open”,”trial_id”:”NCT02028455″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02028455?term=NCT02028455&rank=1″,”cancer_type_terms_string”:”Leukemia (all types)”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/84357″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”February 2014″,”status”:”Open”,”trial_id”:”NCT02099864″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02099864?term=NCT02099864&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02107963?term=NCT02107963&rank=1″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”February 2014″,”status”:”Open”,”trial_id”:”NCT02107963″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02107963?term=NCT02107963&rank=1″,”cancer_type_terms_string”:”Kidney, Melanoma, Sarcoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/85768″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”January 2014″,”status”:”Open”,”trial_id”:”NCT01804465″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01804465?term=NCT01804465&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/78991″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”January 2014″,”status”:”Open”,”trial_id”:”NCT01949337″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01949337?term=NCT01949337&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/81587″,”research_project”:”SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/cutting-fuel-supply-to-pancreatic-cancer-dream-team/”,”start_date”:”January 2014″,”status”:”Open”,”trial_id”:”NCT02030860″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02030860?term=NCT02030860&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/81923″,”research_project”:”SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/cutting-fuel-supply-to-pancreatic-cancer-dream-team/”,”start_date”:”January 2014″,”status”:”Open”,”trial_id”:”NCT02048384″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02048384?term=NCT02048384&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castrationresistant Prostate Cancer With Correlative Assessment of Hormone Intermediates”,”type”:”clinical_trial”,”url”:”https://app2.emergingmed.com/su2c/trial/81522″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”December 2013″,”status”:”Open”,”trial_id”:”NCT02025010″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02025010?term=NCT02025010&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01995058?term=NCT01995058&rank=1″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”December 2013″,”status”:”Closed”,”trial_id”:”NCT01995058″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01995058?term=NCT01995058&rank=1″,”cancer_type_terms_string”:”Prostate, Other”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase I Study of Guadecitabine Combined with Irinotecan Followed by A Randomized Phase II Study of Sgi-110 Combined with Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/77686″,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”start_date”:”October 2013″,”status”:”Open”,”trial_id”:”NCT01896856″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01896856?term=NCT01896856&rank=1″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Chemotherapy, Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/78817″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”October 2013″,”status”:”Open”,”trial_id”:”NCT01946204″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01946204?term=NCT01946204&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/78365″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”October 2013″,”status”:”Open”,”trial_id”:”NCT01928394″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01928394?term=NCT01928394&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/78795″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”September 2013″,”status”:”Open”,”trial_id”:”NCT01942837″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01942837?term=NCT01942837&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/77192″,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”start_date”:”September 2013″,”status”:”Open”,”trial_id”:”NCT01876511″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01876511?term=NCT01876511&rank=1″,”cancer_type_terms_string”:”Colorectal, Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/77306″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”September 2013″,”status”:”Open”,”trial_id”:”NCT01881867″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01881867?term=NCT01881867&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of Rucaparib in Patients With Platinum- Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/77530″,”research_project”:”SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/dna-repair-thearpies-for-ovarian-cancer-dream-team/”,”start_date”:”September 2013″,”status”:”Open”,”trial_id”:”NCT01891344″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01891344?term=NCT01891344&rank=1″,”cancer_type_terms_string”:”Ovarian, Other”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II study evaluating GSK1120212 (MEK) inhibitor alone or in combination with GSK2141795 (AKT inhibitor) in patients with metastatic endometrial cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/78618″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”September 2013″,”status”:”Open”,”trial_id”:”NCT01935973″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01935973?term=NCT01935973&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Randomized Phase II Study of Epigenetic Priming With Azacitidine and Entinostat or Oral Azacitidine Alone Prior to Nivolumab in Subjects With Recurrent Metastatic Non- Small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/78523″,”research_project”:”SU2C Epigenetics Dream Team: Bringing Epigenetic Therapy to the Forefront of Cancer Management”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-therapy-2009-dream-team/”,”start_date”:”August 2013″,”status”:”Open”,”trial_id”:”NCT01928576″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01928576?term=NCT01928576&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Chemotherapy, Epigenetic Therapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Legacy Lung Cancer Trial: A Randomized Phase II Study of Epigenetic Priming with Azacitidine and Entinostat or Oral Azacitidine Alone Prior to Nivolumabin Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/78523″,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”start_date”:”August 2013″,”status”:”Open”,”trial_id”:”NCT01928576″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01928576?term=NCT01928576&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Epigenetic Therapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase 1 Trial of BYL719 Plus Letrozole or Exemestane for Patients with Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/77032″,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”start_date”:”May 2013″,”status”:”Open”,”trial_id”:”NCT01870505″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01870505?term=NCT01870505&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”},{“title”:”Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01935947?term=NCT01935947&rank=1″,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”start_date”:”May 2013″,”status”:”Closed”,”trial_id”:”NCT01935947″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01935947?term=NCT01935947&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”MEDOCC a prospective observational and diagnostic trial to evaluate the prognostic value of circulating tumor DNA after resection of the primary tumor”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02070146?term=NCT02070146&rank=1″,”research_project”:”SU2C–Dutch Cancer Society Colorectal Cancer Early Detection Dream Team: Molecular Early Detection of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-early-detection-dream-team/”,”start_date”:”May 2013″,”status”:”Open”,”trial_id”:”NCT02070146″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02070146?term=NCT02070146&rank=1″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01935947?term=NCT01935947&rank=1″,”research_project”:”SU2C Epigenetics Dream Team: Bringing Epigenetic Therapy to the Forefront of Cancer Management”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-therapy-2009-dream-team/”,”start_date”:”May 2013″,”status”:”Closed”,”trial_id”:”NCT01935947″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01935947?term=NCT01935947&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Chemotherapy, Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/71096″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”April 2013″,”status”:”Open”,”trial_id”:”NCT01637402″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01637402?term=NCT01637402&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”BYL719 and Letrozole in Post-Menopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/74784″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”April 2013″,”status”:”Open”,”trial_id”:”NCT01791478″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01791478?term=NCT01791478&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/88359″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”March 2013″,”status”:”Open”,”trial_id”:”NCT02228265″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02228265?term=NCT02228265&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Investigating Immunobiology in Cancer Patients”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/73702″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”February 2013″,”status”:”Open”,”trial_id”:”NCT01738139″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01738139?term=%22+NCT01738139+%22&rank=1″,”cancer_type_terms_string”:”Kidney, Sarcoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase Ib, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of ARN-509 in Combination With Abiraterone Acetate in Patients With Metastatic Castrate Resistant Prostate Cancer (CRPC)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/74740″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”February 2013″,”status”:”Open”,”trial_id”:”NCT01792687″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01792687?term=NCT01792687&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Pilot study of feasibility and safety of personalized autologous CD8+ T cell therapy plus anti-PD-1 antibody in advanced gastrointestingal malignancies”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/73702″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”February 2013″,”status”:”Open”,”trial_id”:”NCT01738139″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01738139?term=%22+NCT01738139+%22&rank=1″,”cancer_type_terms_string”:”Bile Duct, Colorectal, Esophogeal, Pancreatic, Stomach”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01799278?term=NCT01799278&rank=1″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”February 2013″,”status”:”Open”,”trial_id”:”NCT01799278″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01799278?term=NCT01799278&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer (mCRPC) to Identify Adaptive Mechanisms of Resistance”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT02432001?term=NCT02432001&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”January 2013″,”status”:”Open”,”trial_id”:”NCT02432001″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02432001?term=NCT02432001&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/61040″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”December 2012″,”status”:”Open”,”trial_id”:”NCT01503229″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01503229?term=NCT01503229&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01709734?term=NCT01709734&rank=1″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”December 2012″,”status”:”Open”,”trial_id”:”NCT01709734″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01709734?term=NCT01709734&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) after a Nonmyeloablative Conditioning Regimen, with Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients with Advanced Malignancies”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/72838″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”November 2012″,”status”:”Open”,”trial_id”:”NCT01697527″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01697527?term=NCT01697527&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastastic Colorectal Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/73322″,”research_project”:”SU2C−Dutch Cancer Society Translational Research Team: Prospective Use of DNA-Guided Personalized Cancer Treatment”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/research-teams/dna-guided-care-research-team/”,”start_date”:”November 2012″,”status”:”Open”,”trial_id”:”NCT01719380″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01719380?term=NCT01719380&rank=1″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Research Team”},{“title”:”Detecting EGFR T790M Mutations From Circulating Tumor Cells”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01734915?term=NCT01734915&rank=1″,”research_project”:”SU2C Circulating Tumor Cell Dream Team: Bioengineering and Clinical Applications of Circulating Tumor Cell Chip”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/circulating-tumor-cells-dream-team/”,”start_date”:”November 2012″,”status”:”Open”,”trial_id”:”NCT01734915″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01734915?term=NCT01734915&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”},{“title”:”Test glutamine tracers in patients with localized and resectable PDAC advanced/metastatic disease”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01697930?term=NCT01697930&rank=1″,”research_project”:”SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/cutting-fuel-supply-to-pancreatic-cancer-dream-team/”,”start_date”:”September 2012″,”status”:”Open”,”trial_id”:”NCT01697930″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01697930?term=NCT01697930&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Leukemia (all types), Lung, Lymphoma, Melanoma, Mesothelioma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”},{“title”:”SU2C-CRI-MRA clinical trial with the anti-PD-1 antibody nivolumab and the anti-CTLA4 antibody nivolumab in patients with advanced melanoma. (Trial title: “PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/70850″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”September 2012″,”status”:”Open”,”trial_id”:”NCT01621490″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01621490?term=NCT01621490&rank=1″,”cancer_type_terms_string”:”Melanoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/70877″,”research_project”:”SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/dna-repair-thearpies-for-ovarian-cancer-dream-team/”,”start_date”:”September 2012″,”status”:”Open”,”trial_id”:”NCT01623349″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01623349?term=NCT01623349&rank=1″,”cancer_type_terms_string”:”Breast, Ovarian”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I/ii of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/70877″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”September 2012″,”status”:”Open”,”trial_id”:”NCT01623349″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01623349?term=NCT01623349&rank=1″,”cancer_type_terms_string”:”Breast, Ovarian”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/72371″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”September 2012″,”status”:”Open”,”trial_id”:”NCT01688492″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT02657889?term=NCT02657889&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer (STRIVE)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01664923?term=NCT01664923&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”August 2012″,”status”:”Open”,”trial_id”:”NCT01664923″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01664923?term=NCT01664923&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01578655?term=NCT01578655&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”August 2012″,”status”:”Open”,”trial_id”:”NCT01578655″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01578655?term=NCT01578655&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/72291″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”July 2012″,”status”:”Open”,”trial_id”:”NCT01682772″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01682772?term=NCT01682772&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01594918?term=NCT01594918&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”June 2012″,”status”:”Open”,”trial_id”:”NCT01594918″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01594918?term=NCT01594918&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Trial of BKM120 (a PI3K Inhibitor) in Patients with Triple Negative Metastatic Breast Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01629615?term=NCT01629615&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”June 2012″,”status”:”Open”,”trial_id”:”NCT01629615″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01629615?term=NCT01629615&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01593696?term=NCT01593696&rank=1″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”April 2012″,”status”:”Open”,”trial_id”:”NCT01593696″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01593696?term=NCT01593696&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Lymphoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone- Resistant Prostate Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/69224″,”research_project”:”SU2C−Prostate Cancer Foundation Prostate Dream Team: Precision Therapy of Advanced Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/prostate-cancer-precision-therapy-dream-team/”,”start_date”:”March 2012″,”status”:”Open”,”trial_id”:”NCT01576172″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01576172?term=NCT01576172&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/72292″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”March 2012″,”status”:”Open”,”trial_id”:”NCT01683279″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01683279?term=NCT01683279&rank=1″,”cancer_type_terms_string”:”Leukemia (all types)”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A phase II/pharmacodynamics study of hydroxychloroquine in combination with gemcitabine/ nab-paclitaxel to inhibit autophagy in pancreatic cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/61179″,”research_project”:”SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/cutting-fuel-supply-to-pancreatic-cancer-dream-team/”,”start_date”:”December 2011″,”status”:”Open”,”trial_id”:”NCT01506973″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01506973?term=NCT01506973&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Lymphoma”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01455493?term=NCT01455493&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”December 2011″,”status”:”Open”,”trial_id”:”NCT01455493″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01455493?term=NCT01455493&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Veliparib and Dinaciclib in Patients with Solid tumors”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/58466″,”research_project”:”SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/dna-repair-thearpies-for-ovarian-cancer-dream-team/”,”start_date”:”November 2011″,”status”:”Open”,”trial_id”:”NCT01434316″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01434316?term=NCT01434316&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01497925?term=NCT01497925&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”September 2011″,”status”:”Open”,”trial_id”:”NCT01497925″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01497925?term=NCT01497925&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Development of a Platform for Next-generation DNA Sequencing Based Personalized Treatment for Cancer Patients: Protocol to Obtain Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer (CPCT – 02 Biopsy Protocol)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01855477?term=NCT01855477&rank=1″,”research_project”:”SU2C−Dutch Cancer Society Translational Research Team: Prospective Use of DNA-Guided Personalized Cancer Treatment”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/research-teams/dna-guided-care-research-team/”,”start_date”:”August 2011″,”status”:”Open”,”trial_id”:”NCT01855477″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01855477?term=NCT01855477&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Research Team”},{“title”:”Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01626495?term=NCT01626495&rank=1″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”August 2011″,”status”:”Open”,”trial_id”:”NCT01626495″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01626495?term=NCT01626495&rank=1″,”cancer_type_terms_string”:”Leukemia (all types), Lymphoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II study of ipilimumab plus androgen deprivation therapy in castrate sensitive prostate carcinoma”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01377389?term=NCT01377389&rank=1″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”June 2011″,”status”:”Open”,”trial_id”:”NCT01377389″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01377389?term=NCT01377389&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II Study of MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube or Peritoneal Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01283035?term=NCT01283035&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”April 2011″,”status”:”Open”,”trial_id”:”NCT01283035″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01283035?term=NCT01283035&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin, Ovarian”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients with Advanced Breast Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/53369″,”research_project”:”SU2C Epigenetics Dream Team: Bringing Epigenetic Therapy to the Forefront of Cancer Management”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-therapy-2009-dream-team/”,”start_date”:”April 2011″,”status”:”Open”,”trial_id”:”NCT01349959″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01349959?term=NCT01349959&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01307631?term=NCT01307631&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”March 2011″,”status”:”Open”,”trial_id”:”NCT01307631″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01307631?term=NCT01307631&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Akt Inhibitor MK2206 in Treating Patients with Advanced Breast Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01277757?term=NCT01277757&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”March 2011″,”status”:”Open”,”trial_id”:”NCT01277757″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01277757?term=NCT01277757&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”MK2206 and Paclitaxel in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01263145?term=NCT01263145&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”January 2011″,”status”:”Open”,”trial_id”:”NCT01263145″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01263145?term=NCT01263145&rank=1″,”cancer_type_terms_string”:”Bile Duct, Bladder, Brain/Nervous System, Breast, Cervical, Colorectal, Endometiral/Uterin, Esophogeal, Gall Bladder, Head and Neck, Kidney, Liver, Lung, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian, Pancreatic, Prostate, Sarcoma, Stomach, Testicular, Other”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase 1, Dose-Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01261312?term=NCT01261312&rank=1″,”research_project”:”SU2C Epigenetics Dream Team: Bringing Epigenetic Therapy to the Forefront of Cancer Management”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-therapy-2009-dream-team/”,”start_date”:”December 2010″,”status”:”Open”,”trial_id”:”NCT01261312″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01261312?term=NCT01261312&rank=1″,”cancer_type_terms_string”:”Leukemia (all types)”,”treatment_type_terms_string”:”Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01185509?term=NCT01185509&rank=1″,”research_project”:”SU2C Circulating Tumor Cell Dream Team: Bioengineering and Clinical Applications of Circulating Tumor Cell Chip”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/circulating-tumor-cells-dream-team/”,”start_date”:”November 2010″,”status”:”Closed”,”trial_id”:”NCT01185509″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01185509?term=NCT01185509&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Screening/ Early Detection, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase Ib BKM120 or BEZ235 + Endocrine Treatment in Post-Menopausal Patients with Hormone Receptor + Metastatic Breast Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01248494?term=NCT01248494&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”November 2010″,”status”:”Open”,”trial_id”:”NCT01248494″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01248494?term=NCT01248494&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/48157″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”October 2010″,”status”:”Open”,”trial_id”:”NCT01109095″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01109095?term=NCT01109095&rank=1″,”cancer_type_terms_string”:”Brain/Nervous System, Head and Neck”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A study of 80 patients with advanced Stage IV pancreatic cancer in a Phase I/II trial of gemcitabine + nab-paclitaxel + GDC-0449″,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01088815?term=NCT01088815&rank=1″,”research_project”:”SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/cutting-fuel-supply-to-pancreatic-cancer-dream-team/”,”start_date”:”September 2010″,”status”:”Open”,”trial_id”:”NCT01088815″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01088815?term=NCT01088815&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Neoadjuvant Phase IIa Study of Ipilimumab {formerly known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men with Prostate Cancer Followed by Radical Prostatectomy”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01194271?term=NCT01194271&rank=1″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”September 2010″,”status”:”Open”,”trial_id”:”NCT01194271″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01194271?term=NCT01194271&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01196247?term=NCT01196247&rank=1″,”research_project”:”SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/cutting-fuel-supply-to-pancreatic-cancer-dream-team/”,”start_date”:”September 2010″,”status”:”Open”,”trial_id”:”NCT01196247″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01196247?term=NCT01196247&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Dream Team”},{“title”:”Randomized phase II trial of adjuvant combined epigenetic therapy with 5-azacitidine and entinostat in resected stage I non-small cell lung cancer versus standard of care”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01207726?term=NCT01207726&rank=1″,”research_project”:”SU2C Epigenetics Dream Team: Bringing Epigenetic Therapy to the Forefront of Cancer Management”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-therapy-2009-dream-team/”,”start_date”:”September 2010″,”status”:”Closed”,”trial_id”:”NCT01207726″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01207726?term=NCT01207726&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Chemotherapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01253642?term=NCT01253642&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”July 2010″,”status”:”Closed”,”trial_id”:”NCT01253642″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01253642?term=NCT01253642&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Study OF xl147 OR xl765 in Combination with Letrozole in Subjects with Breast Cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01082068?term=NCT01082068&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”June 2010″,”status”:”Open”,”trial_id”:”NCT01082068″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01082068?term=NCT01082068&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01212991?term=NCT01212991&rank=1″,”research_project”:”SU2C–Prostate Cancer Foundation Prostate Dream Team: Targeting Adaptive Pathways in Metastatic Castration-Resistant Prostate Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/metastatic-treatment-resistant-prostate-cancer-dream-team/”,”start_date”:”June 2010″,”status”:”Open”,”trial_id”:”NCT01212991″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01212991?term=NCT01212991&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase II study of azacitidine and entinostat in patients with metastatic colorectal cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01105377?term=NCT01105377&rank=1″,”research_project”:”SU2C Epigenetics Dream Team: Bringing Epigenetic Therapy to the Forefront of Cancer Management”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-therapy-2009-dream-team/”,”start_date”:”April 2010″,”status”:”Open”,”trial_id”:”NCT01105377″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01105377?term=NCT01105377&rank=1″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Chemotherapy, Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/79435″,”research_project”:”SU2C Circulating Tumor Cell Dream Team: Bioengineering and Clinical Applications of Circulating Tumor Cell Chip”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/circulating-tumor-cells-dream-team/”,”start_date”:”April 2010″,”status”:”Open”,”trial_id”:”NCT01961713″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01961713?term=NCT01961713&rank=1″,”cancer_type_terms_string”:”Prostate”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”},{“title”:”Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2)”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/46485″,”research_project”:”SU2C−Dutch Cancer Society Translational Research Team: Prospective Use of DNA-Guided Personalized Cancer Treatment”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/research-teams/dna-guided-care-research-team/”,”start_date”:”March 2010″,”status”:”Open”,”trial_id”:”NCT01042379″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01042379?term=NCT01042379&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Research Team”},{“title”:”Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/42857″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”February 2010″,”status”:”Open”,”trial_id”:”NCT00902044″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00902044?term=NCT00902044&rank=1″,”cancer_type_terms_string”:”Sarcoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT00997334?term=NCT00997334&rank=1″,”research_project”:”SU2C Circulating Tumor Cell Dream Team: Bioengineering and Clinical Applications of Circulating Tumor Cell Chip”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/circulating-tumor-cells-dream-team/”,”start_date”:”February 2010″,”status”:”Open”,”trial_id”:”NCT00997334″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00997334?term=NCT00997334&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Chemotherapy, Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”},{“title”:”Study of XL147 in Combination with Trastuzumab or Paclitaxel and Trastuzumab in Subjects with Metastatic Breast Cancer Who have Progressed on a Previous Trastuzumab-based Regimen”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01042925?term=NCT01042925&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”February 2010″,”status”:”Open”,”trial_id”:”NCT01042925″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01042925?term=NCT01042925&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients with Stage III, Stage IV, or Recurrent Endometrial Cancer”,”type”:”clinical_trial”,”url”:”https://app.emergingmed.com/su2c/trial/44776″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”September 2009″,”status”:”Open”,”trial_id”:”NCT00977574″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00977574?term=NCT00977574&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase II Evaluation of AZD6244 in the Treatment of Recurrent or Persistent Endometrial Carcinoma”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT01011933?term=NCT01011933&rank=1″,”research_project”:”SU2C PI3K Dream Team: Targeting the PI3K Pathway in Women’s Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/womens-cancers-pi3k-dream-team/”,”start_date”:”September 2009″,”status”:”Open”,”trial_id”:”NCT01011933″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT01011933?term=NCT01011933&rank=1″,”cancer_type_terms_string”:”Endometiral/Uterin”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy (HERCREEM)”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT00889954?term=NCT00889954&rank=1″,”research_project”:”SU2C–St. Baldrick’s Foundation Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/high-risk-pediatric-cancers-dream-team/”,”start_date”:”May 2009″,”status”:”Open”,”trial_id”:”NCT00889954″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00889954?term=NCT00889954&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”Phase 3 Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT00844649?term=NCT00844649&rank=1″,”research_project”:”SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/cutting-fuel-supply-to-pancreatic-cancer-dream-team/”,”start_date”:”March 2009″,”status”:”Open”,”trial_id”:”NCT00844649″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00844649?term=NCT00844649&rank=1″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”Novel (PD 0332991: CDK4/6 inhibitor, Pfizer); ER Positive, HER2 Negative Advanced Breast Cancer In Postmenopausal Women”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT00721409?term=NCT00721409&rank=1″,”research_project”:”SU2C Breast Cancer Dream Team: An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their Resistance Phenotypes”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/breast-cancer-resistant-phenotypes-dream-team/”,”start_date”:”September 2008″,”status”:”Open”,”trial_id”:”NCT00721409″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00721409?term=NCT00721409&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer”,”type”:”clinical_trial”,”url”:”https://app2.emergingmed.com/su2c/trial/26242″,”research_project”:”SU2C Circulating Tumor Cell Dream Team: Bioengineering and Clinical Applications of Circulating Tumor Cell Chip”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/circulating-tumor-cells-dream-team/”,”start_date”:”May 2007″,”status”:”Open”,”trial_id”:”NCT00470704 “,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00470704?term=NCT00470704&rank=1″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Chemotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A Phase 1b Safety and Dose-Assessment Study of Neoadjuvant Ipilimumab Monotherapy in Patients With Urothelial Carcinoma Undergoing Surgical Resection”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT00362713?term=NCT00362713&rank=1″,”research_project”:”SU2C–Cancer Research Institute Cancer Immunology Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/immunologic-checkpoint-blockade-dream-team/”,”start_date”:”March 2007″,”status”:”Open”,”trial_id”:”NCT00362713″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00362713?term=NCT00362713&rank=1″,”cancer_type_terms_string”:”Bladder, Leukemia (all types)”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”},{“title”:”A phase I/II study of MS275 in combination with 5-azacitidine in patients with recurrent advanced nonsmall cell lung cancer”,”type”:”clinical_trial”,”url”:”https://clinicaltrials.gov/ct2/show/NCT00387465?term=NCT00387465&rank=1″,”research_project”:”SU2C Epigenetics Dream Team: Bringing Epigenetic Therapy to the Forefront of Cancer Management”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-therapy-2009-dream-team/”,”start_date”:”August 2006″,”status”:”Open”,”trial_id”:”NCT00387465″,”trial_url”:”https://clinicaltrials.gov/ct2/show/NCT00387465?term=NCT00387465&rank=1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Chemotherapy, Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”}],”total_count”:204,”total_pages”:0,”type”:”clinical_trial”}

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.